This site requires JavaScript and cookies to be enabled.

Access and support
for your patients
and your practice

Tools to help you and your patients navigate Qelbree coverage and support for you and your office.

Prescribing Qelbree

Pay as little as $20 for a 30 day or 90-day prescription

Commercially insured patients may pay as little as $20 for a 30-day or 90-day prescription.*

*Terms and conditions apply.

The Qelbree Savings Card can lower
out-of-pocket costs.

Qelbree offers a savings card to eligible patients. You can give your patients access to this savings card by emailing or printing the savings card.

Get a savings card 


This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

For additional information about the Qelbree Patient Savings and Support Program, call 1-866-398-0833.

 

The image depicts the covermymeds logo, featuring orange and pink text.

CoverMyMeds is a HIPAA-compliant website that helps you streamline and automate your prior authorization process.

Speeding up prior authorization with CoverMyMeds

Easy access through covermymeds.com, the NaviNet national multipayer portal for your office's electronic health records or clinical system.

Efficient search engine that finds the best prior authorization request for almost all drug plans in seconds. Complete and submit the request online in minutes.

100% free to all healthcare providers.

Log in 

Considering Qelbree

Two sample bottles of Qelbree (viloxazine) extended-release capsules in 100 mg and 200 mg doses.

Offer free samples to your patients

Sign up to request Qelbree samples to be sent to your office.

Request samples

 

Learn about Qelbree by speaking to a rep

Supernus has built a 30-year legacy in the neurological space. Part of this commitment to patients and healthcare providers includes an expansive support system including access to representatives.

Request a representative 

 

Supernus® Support logo

Supernus Support

Supernus Support can check insurance benefits and connect patients to savings programs for patients worried about paying for Qelbree. Submit a request via form or reach out via phone.

Call 1-866-398-0833. Open Monday to Friday from 8:30 AM to
6:30 PM EST.

Complete request form 

 

Qelbree is available at pharmacies nationwide, including Amazon Pharmacy

A prescription for Qelbree can be fulfilled at pharmacies nationwide, including online through Amazon Pharmacy.

Hear provider perspectives on Qelbree and ADHD

Hear the latest peer perspectives from leaders in the field of ADHD management. Subscribe to All About ADHD, a YouTube channel provided by the Qelbree team as part of a commitment to advancing the treatment, education, and management of ADHD.

Watch All About ADHD

Abbreviation: ADHD, attention-deficit/hyperactivity disorder.

Discover more:

Switch to Qelbree  Qelbree dosing  FAQs 

What your peers are saying about Qelbree

 

Our patients really appreciate the samples, they like the coupons that can help them with their insurance, so it's more affordable for them.

– Deena Gandhi, MD

Watch their video

 

I have samples to get them started on. We can work at starting it and titrating it to get to the right dose, and then I can send a prescription into the pharmacy.

– Birgit Amann, MD

Watch their video

Stay informed

Get Qelbree email updates, savings information, and links to helpful resources for you and your patients.

Sign up 

IMPORTANT SAFETY INFORMATION

INDICATION

Qelbree (viloxazine extended-release capsules) is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older.

IMPORTANT SAFETY INFORMATION

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS

In clinical studies, higher rates of suicidal thoughts and behaviors were reported in [read more] patients with ADHD treated with Qelbree than in patients treated with placebo. Closely monitor all Qelbree-treated patients for clinical worsening and for emergence of suicidal thoughts and behaviors.

In clinical studies, higher rates of suicidal thoughts and behaviors were reported in patients with ADHD treated with Qelbree than in patients treated with placebo. Closely monitor all [read more] Qelbree-treated patients for clinical worsening and for emergence of suicidal thoughts and behaviors.

CONTRAINDICATIONS

  • Concomitant administration of a monoamine oxidase inhibitor (MAOI), or dosing within 14 days after discontinuing an MAOI, because of an increased risk of hypertensive crisis
  • Concomitant administration of sensitive CYP1A2 substrates or CYP1A2 substrates with a narrow therapeutic range

WARNINGS & PRECAUTIONS

  • Suicidal thoughts and behaviors: Closely monitor all Qelbree-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors, especially during the initial few months of drug therapy, and at times of dosage changes
  • Heart rate, blood pressure increases: Qelbree can cause an increase in diastolic blood pressure and heart rate. Assess these measures prior to starting therapy, following increases in dosage, and periodically during therapy
  • Activation of mania or hypomania: Noradrenergic drugs may induce a manic or mixed episode in patients with bipolar disorder. Prior to initiating treatment with Qelbree, screen patients to determine if they are at risk for bipolar disorder. Screening should include a detailed psychiatric history, including a personal or family history of suicide, bipolar disorder, and depression 
  • Somnolence and fatigue: Patients should not perform activities requiring mental alertness, such as operating a motor vehicle or hazardous machinery, due to potential somnolence (including sedation or lethargy) and fatigue, until they know how they will be affected by Qelbree 

ADVERSE REACTIONS

The most common adverse reactions (≥ 5% and at least twice the rate of placebo for any dose) in patients 6 to 17 years were somnolence, decreased appetite, fatigue, nausea, vomiting, insomnia, and irritability, and in adults, insomnia, headache, somnolence, fatigue, nausea, decreased appetite, dry mouth, and constipation. 

PREGNANCY

There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to Qelbree during pregnancy. Healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for Psychiatric Medications at 1-866-961-2388 or by visiting www.womensmentalhealth.org/preg. 

Please see full Prescribing Information, including Boxed Warning.

IMPORTANT SAFETY INFORMATION

INDICATION

Qelbree (viloxazine extended-release capsules) is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older.

IMPORTANT SAFETY INFORMATION

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS

In clinical studies, higher rates of suicidal thoughts and behaviors were reported in [read more] patients with ADHD treated with Qelbree than in patients treated with placebo. Closely monitor all Qelbree-treated patients for clinical worsening and for emergence of suicidal thoughts and behaviors.

In clinical studies, higher rates of suicidal thoughts and behaviors were reported in patients with ADHD treated with Qelbree than in patients treated with placebo. Closely monitor all [read more] Qelbree-treated patients for clinical worsening and for emergence of suicidal thoughts and behaviors.

CONTRAINDICATIONS

  • Concomitant administration of a monoamine oxidase inhibitor (MAOI), or dosing within 14 days after discontinuing an MAOI, because of an increased risk of hypertensive crisis
  • Concomitant administration of sensitive CYP1A2 substrates or CYP1A2 substrates with a narrow therapeutic range

WARNINGS & PRECAUTIONS

  • Suicidal thoughts and behaviors: Closely monitor all Qelbree-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors, especially during the initial few months of drug therapy, and at times of dosage changes
  • Heart rate, blood pressure increases: Qelbree can cause an increase in diastolic blood pressure and heart rate. Assess these measures prior to starting therapy, following increases in dosage, and periodically during therapy
  • Activation of mania or hypomania: Noradrenergic drugs may induce a manic or mixed episode in patients with bipolar disorder. Prior to initiating treatment with Qelbree, screen patients to determine if they are at risk for bipolar disorder. Screening should include a detailed psychiatric history, including a personal or family history of suicide, bipolar disorder, and depression 
  • Somnolence and fatigue: Patients should not perform activities requiring mental alertness, such as operating a motor vehicle or hazardous machinery, due to potential somnolence (including sedation or lethargy) and fatigue, until they know how they will be affected by Qelbree 

ADVERSE REACTIONS

The most common adverse reactions (≥ 5% and at least twice the rate of placebo for any dose) in patients 6 to 17 years were somnolence, decreased appetite, fatigue, nausea, vomiting, insomnia, and irritability, and in adults, insomnia, headache, somnolence, fatigue, nausea, decreased appetite, dry mouth, and constipation. 

PREGNANCY

There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to Qelbree during pregnancy. Healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for Psychiatric Medications at 1-866-961-2388 or by visiting www.womensmentalhealth.org/preg. 

Please see full Prescribing Information, including Boxed Warning.